Navigation Links
Second-line CML drugs evoke faster, better front-line remissions
Date:6/5/2010

dose nilotinib, the numbers were 78 percent, 43 percent and also less than 1 percent.

In the imatinib arm, 65 percent achieved complete cytogenetic response, 22 percent reached major molecular response, and 4 percent had their disease progress.

Patients on nilotinib achieved major molecular response earlier than those on imatinib, with median times to MMR of 5.7 and 5.8 months, compared with 8.3 months for imatinib.

Nilotinib and imatinib had favorable safety profiles, with serious side effects uncommon for either drug. Hematologic side effects decreased levels of red blood cells, white blood cells or platelets -- were slightly more common among those on imatinib. Nausea, diarrhea, vomiting, muscle spasms and edema were higher on imatinib, but rash, headache, hair loss and itching were higher on nilotinib.

Novartis, the company that makes imatinib, also developed nilotinib, and Bristol-Myers Squibb developed dasatinib, both of which are more potent inhibitors of the BCR-ABL protein. The two drugs are approved as second-line therapy after imatinib fails or as first therapy for those who cannot take imatinib. Both companies are expected to seek U.S. Food and Drug Administration approval for the two drugs as initial therapy for CML.

"Findings from both of these studies confirm the single-arm trials done at MD Anderson, which had shown superiority of second-generation drugs in a front-line setting," Kantarjian said. The two ongoing single-arm clinical trials, led by Jorge Cortes, M.D., professor in MD Anderson's Department of Leukemia, compare the performance of the drugs in new patients to historical results from earlier trials of imatinib.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Second-line CML drugs evoke faster response than front-line therapy
2. Patient age not a factor in use of second-line therapy for lung cancer
3. Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
4. New Drugs, New Combinations Fight Breast Cancer
5. NICE guidelines ration affordable osteoporosis drugs
6. Bone Drugs May Beat Back Breast Cancer
7. Rehabilitation for Opiate Addiction Without Maintenance Drugs
8. Review and approval of oncology and hematology drugs at FDA from 2005 to 2007
9. Fake Drugs Bought on the Web Pose Big Health Risks
10. Scientists show how molecular switch helps pancreatic cancer beat drugs
11. Common antidepressant drugs linked to lactation difficulties in moms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... 2015 , ... Brands like Toppik , Eau Thermale Avene and Bliss ... a threshold of $49.00 was required to qualify for free standard shipping,” said Jennifer ... shipping for customers regardless of the item’s selling price.” , With competitive pricing in ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 ... contains 15 seconds of unique footage that users can shrink and stretch in the ... and more. Users can customize color, brightness, scale, speed, range, and flare attributes with ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain ... with stretching, soft tissue manipulation. Platelet rich plasma injections also have mixed ... to improve treatment outcomes. This localized treatment seems to address the symptoms ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular ... market and sell Arterosil and Arterosil HP, and that all claims and counterclaims ... Vascular Health Sciences, LLC (VHS) in the United States District Court for the ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... , FRIDAY, Dec. 30 (HealthDay News) -- ... and skaters should take simple safety precautions, orthopedic experts ... that in 2010 more than 440,000 people were treated ... among snowboarders and skiers. These two sports accounted for ...
... Two recent studies by Van Andel Research Institute scientists ... distinct kidney cancer subtypes, which could pave the way for ... Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, ... of Type 2 papillary renal cell carcinoma (PRCC2), an aggressive ...
... Dennis Thompson HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay ... was 19 years old. Then a sophomore studying physics at ... and depression for years. He said he,d self-medicated by drinking and ... demons that had been gnawing at his soul for years burst ...
... 2011 revision of the International Standards for the Neurological ... the November 2011 issue of the Journal of ... Steven Kirshblum et al clarifies the modifications to this ... http://www.ingentaconnect.com/content/maney/scm (#6, Nov 2011). ISNCSCI ...
... -- A new review of existing research suggests that, despite ... heart patients should get Plavix, a blood-thinning drug used to ... clopidogrel, is used to treat or prevent blood clots due ... as balloon angioplasty. But some patients ...
... Dennis Thompson HealthDay Reporter , WEDNESDAY, Dec. 28 ... are typically thought to be diseases of young women and ... drive a young person to an eating disorder may linger ... are coming forward to receive treatment for eating problems that ...
Cached Medicine News:Health News:Tips to Keep Winter Sports Injury-Free 2Health News:Tips to Keep Winter Sports Injury-Free 3Health News:Van Andel Research Institute findings provide more complete picture of kidney cancer 2Health News:Virginia Man Won't Let His Mental Illness Define Him 2Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Doubt Cast on Use of Genetic Test Before Plavix 2Health News:Eating Disorders Can Last Well Beyond Teen Years 2Health News:Eating Disorders Can Last Well Beyond Teen Years 3
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Quetiapine Market, 2010-2019" ... by AstraZeneca plc, quetiapine (under the trade name ... treatment of schizophrenia. Approved by CFDA to treat ... Catalogue of Drugs for the Basic National Medical ...
(Date:8/28/2015)... HONG KONG , August 28, 2015 ... Gero in collaboration with one of the leading academics ... Reis (current world record holder in life extension for ... new insights into biology of aging and age-related diseases, primarily, ... networks. The work has just been published as "Stability analysis ...
(Date:8/28/2015)... Denmark and ATLANTA ... 31, 2015 the US Food and Drug Administration (FDA) cleared ... Depressive Disorder in adult patients who have failed to receive ... TMS is a non-invasive technique for stimulating neural tissue in ... Major Depressive Disorder. The procedure has been proven safe and ...
Breaking Medicine Technology:China Quetiapine Market Investigation Report 2010-2019 2Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... 2012 Sequenom, Inc. (NASDAQ: SQNM ) today announced ... other conditions, shares of its common stock in an underwritten public ... the offering may be completed, or as to the actual size ... is acting as sole book-running manager for the offering.  ...
... Gore & Associates is among just five workplaces to ... to Work For" since the rankings debuted three decades ... its workforce, earned the No. 38 spot on the ... (Photo:  http://photos.prnewswire.com/prnh/20120119/PH38553 ) Headquartered in Newark, Del., ...
Cached Medicine Technology:Sequenom Announces Proposed Public Offering of Common Stock 2W. L. Gore & Associates Named a Top U.S. Workplace 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: